CLL TIM risk model predicts infection and treatment need in newly diagnosed chronic lymphocytic leukaemia
CLL TIM risk model predicts infection and treatment need in newly diagnosed chronic lymphocytic leukaemia
Metronomic chemo plus nivolumab (TMC-I) improves survival in R/M head & neck cancer vs platinum chemotherapy
ASCO 2026: Comment: Multi-cancer earlier detection tests
Mobile app-based symptom monitoring helps maintain quality of life in advanced cancer
Cytoreductive SBRT with ipilimumab and nivolumab in de novo mRCC shows no PFS benefit but is safe
ArteraAI MMAI enhances prediction of biochemical recurrence and metastasis in localised prostate cancer
The Vanessa Moss Prize: celebrating research into cancer health disparities
Improving cancer care by partnering not-for-profits based in the UK and Ireland with colleagues in LMICs
An overview of LGCW 2025
Innovating cancer care access for low and middle-income countries
Rebuilding trust in healthcare in historically marginalised communities
Evolving conversations on value and equity in cancer care